WEDNESDAY, 12 JUNE 2019

18.15 - 19.45 Hall 8

AbbVie
Achieving remission in RA: Elevating expectations

Chair(s):
Peter Taylor (UK)

Peter Taylor (UK) 18.15
Welcome and introduction

Maya Buch (UK) 18.20
What defines remission?

Peter Taylor (UK) 18.35
Why drive for remission?

Claire Bombardier (CA) 18.55
Achieving remission in the real world

Peter Nash (AU) 19.15
Can new therapies elevate our expectations

All 19.35
Panel discussion and Q&A

18.15 - 19.45 Hall 7A

Pfizer
Exploring advanced therapeutic options in rheumatoid arthritis (RA) and psoriatic arthritis (PsA): A case-driven approach

Chair(s):
Juan Gómez-Reino (ES)

Juan Gómez-Reino (ES) 18.15
Welcome and introductions

Janet Pope (CA) 18.20
Patients with inadequate response to csDMARDs in RA

Janet Pope (CA) 18.40
Patients who are candidates for monotherapy in RA

Douglas Veale (IR) 19.00
Patients presenting with joint symptoms and fatigue in PsA

James Galloway (UK) 19.20
Patients presenting with associated comorbidities in RA/PsA

Juan Gómez-Reino (ES) 19.40
Summary and close

18.15 - 19.45 Hall 7B

Sanofi Genzyme Regeneron
Metacognition in RA: Thinking about our thinking in RA management

Chair(s):
Leonard Calabrese (US)

Leonard Calabrese (US) 18.15
Introduction: Is it possible to achieve better disease control in RA?

John Weinman (UK) 18.25
The role of patient beliefs in RA adherence and therapy optimisation

Daniel Aletaha (AT) 18.40
The ideal vs the norm: What does minimally important difference mean and why is this important in management of RA today?

Andrea Rubbert-Roth (CH) 18.55
Changes in daily RA practice: Dealing with loss vs gain in switching vs cycling

Leonard Calabrese (US) 19.10
Holistic care of patients with RA

All 19.20
Q&A

Leonard Calabrese (US) 19.40
Close

18.15 - 19.45 N101/N102

Novartis
Targeting clinical remission in Still’s disease with interleukin-1β inhibition

Chair(s):
Sinisa Savic (UK)

Sinisa Savic (UK) 18.15
Welcome and introductions

Sinisa Savic (UK) 18.20
Still’s disease – a devastating condition for young and adult patients

Eugen Feist (DE) 18.40
IL-1β inhibition in adult-onset Still’s disease: From successful case experiences to clinical trials

Pierre Quartier (FR) 19.00
Flexibility in the management of systemic juvenile idiopathic arthritis with IL-1β inhibition

All 19.20
Panel discussion: Current and future perspectives on targeting remission
**18.15 - 19.45** N117/N118

**IBSA**

Management of pain in osteoarthritis: From clinical guidelines to real life

**Chair(s):**
Jean-Yves Reginster (BE)

**Jean-Yves Reginster (BE)**
Welcome and introduction

**Marc Hochberg (US)**
Current recommendations for the management of osteoarthritis

**Alberto Migliore (IT)**
OA treatment: One fits for all?

**Alberto Migliore (IT)**
Towards the appropriate choice of hyaluronic acid product for «my patient»

**Jean-Yves Reginster (BE)**
Efficacy and safety of a single intra-articular injection of high and low molecular weight hyaluronic acid in the symptomatic management of knee osteoarthritis

**All**
Discussion and conclusion

---

**18.15 - 19.45** N111/N112

**Fresenius Kabi**

Beyond the joint: An integrated approach to rheumatoid arthritis

**Chair(s):**
Josef S. Smolen (AT)

**Josef S. Smolen (AT)**
Welcome and introduction

**Bruno Fautrel (FR)**
Expanding access to biologics with biosimilars

**Anne Tournadre (FR)**

**Chris Edwards (UK)**
Rheumatoid Arthritis (RA) – the impact of comorbidities: A focus on sarcopenia and mental health disorders

**Chris Edwards (UK)**
Management of RA patients beyond the disease

**Josef S. Smolen (AT)**
Conclusion and structured discussion

---

**THURSDAY, 13 JUNE 2019**

**08.15 - 09.45** Hall 8

**AbbVie**

Therapeutic choice in RA: How should we be guided by patients?

**Chair(s):**
Andrew Östör (AU)

**Andrew Östör (AU)**
Welcome and introduction

**Jose Maria Alvaro-Gracia (ES)**
The impact of RA on quality of life: The patient perspective

**Lars Klareskog (SE)**
Assessing patient outcomes in routine clinical practice: Can we do better?

**David Walsh (UK)**
Pain mechanisms and management in RA

**All**
Patient-centric therapeutic choice

**All**
Panel discussion and Q&A

---

**08.15 - 09.45** Hall 7A

**Novartis**

Axial spondyloarthritis: Optimizing clinical management and future directions

**Chair(s):**
Robert Landewé (NL)

**Robert Landewé (NL)**
Welcome and introduction

**Robert Landewé (NL)**
Radiographic and non-radiographic axSpA: Historical perspectives and current priorities

**Georg Schett (DE)**
Optimizing the axSpA patient journey: Clinical spectrum and pathophysiology

**Lianne Gensler (US)**
Clinical cases in axSpA management: Early diagnosis and assessment

**Denis Poddubnyy (DE)**
Therapies in the management of axSpA

**All**
Panel discussion and conclusions
**Roche**

*Putting new evidence into clinical practice in GCA and RA – together we dare*

Chair(s):
John Stone (US)

John Stone (US)
New insights into the treatment of GCA

Frank Buttgerit (DE)
Strengthening the treatment paradigm in RA

**Lilly**

*Elevating treatment goals in psoriatic arthritis*

Chair(s):
Victoria Navarro-Compán (ES)
Lars Erik Kristensen (DK)

Victoria Navarro-Compán (ES)
Lars Erik Kristensen (DK) 08.15
Welcome and introduction

Lars Erik Kristensen (DK) 08.20
Can we elevate treatment goals for patients with psoriatic arthritis?

Dennis McGonagle (UK) 08.40
The leading role of IL-17's in the treatment of psoriatic arthritis

Peter Nash (AU) 09.00
Ixekizumab in the holistic management of psoriatic arthritis: SPIRIT head to head trial

All 09.20
Panel discussion: What does the data mean for patients?

**medac**

*MTX remains gold standard in the era of biologics and new therapies*

Chair(s):
Carter Thorne (CA)

Carter Thorne (CA) 08.15
Welcome and introduction

Carter Thorne (CA) 08.20
Benefits of subcutaneous vs oral methotrexate in RA treatment

**Gerolamo Blanchi (IT)** 08.45
Optimising MTX therapy to improve treatment outcomes

**Pavia Dolezalova (CZ)** 09.10
Improving treatment outcomes in patients with juvenile idiopathic arthritis

**Carter Thorne (CA)** 09.35
Summary and discussion

**UCB**

*Considering the patient perspective: Challenges facing women with axSpA and PsA*

Chair(s):
Irene van der Horst-Bruinsma (NL)

Irene van der Horst-Bruinsma (NL) 08.15
Welcome and introduction

Helena Marzo-Ortega (UK)

Kay Anderson (UK) 08.30
Expert discussion: axSpA

Laura Coates (UK)

Kay Anderson (UK) 09.00
Expert discussion: PsA

All 09.30
Summary and question and answer discussion

**Biogen and Samsung Bioepis**

*Optimizing patient management in RA – Can we live up to patient expectations?*

Chair(s):
Peter Taylor (UK)

Peter Taylor (UK) 08.15
Opening and introduction

Peter Taylor (UK)
Marco Matucci Cerinic (IT)
Ulf Mueller-Ladner (DE)
Ruth Slack (UK)

Thierry Thomas (FR) 08.30
1) Selecting the right treatment for the right patient at the right time: What drives our decision? 2) Patient expectations in RA 3) Addressing patient expectations: Through the eyes of a multidisciplinary team

Peter Taylor (UK) 09.40
Closing remarks

**Controversial topics debate and Q&A**
08.15 - 09.45  N111/N112

PeerVoice
supported by Sanofi Genzyme
IL-6 receptor inhibition in RA: New perspectives in optimal patient care

Chair(s):
Ernest Choy (UK)

Ernest Choy (UK) 08.15
Welcome and introduction

Ernest Choy (UK) 08.20
IL-6 biology and implications for clinical targeting in RA

Roberto Caporali (IT) 08.45
Differentiating IL-6R inhibitors from other drug classes

Jacques-Eric Gottenberg (FR) 09.10
Optimising IL-6R inhibition in clinical practice

Ernest Choy (UK) 09.35
Conclusion

17.30 - 19.00  Hall 7B

Medscape
supported by Pfizer and Lilly
Managing chronic pain in osteoarthritis: Pushing back the frontier with targeted therapies

Chair(s):
Richard Langford (UK)

Faculty:
Francis Berenbaum (FR)
Bart Morlion (BE)
Cécile Overman (NL)

Part 1: Treatment strategies for osteoarthritis-associated pain: A case journey

Part 2: OA-associated chronic pain: What is the therapeutic “frontier”?

Closing

17.30 - 19.00  N101/N102

AbbVie
Demystifying the systemic truths of SpA

Chair(s):
Dirk Elewaut (BE)

Dirk Elewaut (BE) 17.30
Welcome and introduction

Demystifying the journey from pathogenesis to therapy

Dafna Gladman (CA) 17.55
Unmet needs in SpA: Not just the usual suspects

Laura Coates (UK) 18.20
Integrated, personalised, connected…SpA 2025

All 18.40
Panel discussion and Q&A

17.30 - 19.00  Hall 7A

Janssen
Fine-tuning the treatment of PsA: Focus on the IL-23 pathway

Chair(s):
Georg Schett (DE)
Peter Taylor (UK)

Georg Schett (DE) 17.30
Welcome and introduction

Stefan Siebert (UK) 17.35
The promise and delivery of targeting the IL-12/23 pathway

Georg Schett (DE) 17.50
Focus on the IL-23 pathway

Peter Taylor (UK) 18.05
Targeting IL-23: What could this mean in practice?

Lluís Puig (ES) 18.20
Experience of targeting IL-23 in dermatology

All 18.35
Panel discussion and Q&A

Georg Schett (DE) 18.55
Conclusions and close of meeting
### 17.30 - 19.00  N105/N106

**Bristol-Myers Squibb**  
**Beyond the joint: The role of pathogenic autoantibodies in system manifestations of RA**

**Chair(s):**  
Bernard Combe (FR)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Affiliation</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.30</td>
<td>Bernard Combe (FR)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17.35</td>
<td>Jens Thiel (DE)</td>
<td>The course of systemic RA disease: The role of pathogenic autoantibodies</td>
</tr>
<tr>
<td>17.55</td>
<td>José María Álvaro-Gracia (ES)</td>
<td>Unseen epidemic: Causes and consequences of RA-associated ILD</td>
</tr>
<tr>
<td>18.20</td>
<td>Laura Geraldino-Pardilla (US)</td>
<td>Double trouble: Autoimmunity and inflammation link to cardiovascular risk in RA</td>
</tr>
<tr>
<td>18.45</td>
<td>All</td>
<td>Symposium summary, panel discussion and close</td>
</tr>
</tbody>
</table>

### 17.30 - 19.00  N111/N112

**Celltrion Healthcare**  
**Redesigning the future of RA treatment with Infliximab SC**

**Chair(s):**  
Rieke Alten (DE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Affiliation</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.30</td>
<td>Rieke Alten (DE)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17.40</td>
<td>DaeHyun Yoo (KR)</td>
<td>Real-world safety, efficacy and drug survival of CT-P13</td>
</tr>
<tr>
<td>18.10</td>
<td>Rene Westhovens (BE)</td>
<td>Clinical findings on CT-P13 SC</td>
</tr>
<tr>
<td>18.40</td>
<td>All</td>
<td>Panel discussion</td>
</tr>
</tbody>
</table>

### FRIDAY, 14 JUNE 2019

### 08.15 - 09.45  Hall 7A

**Novartis**  
**IL-17A inhibition in psoriatic arthritis: Comprehensive treatment across disease manifestations**

**Chair(s):**  
Paul Emery (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Affiliation</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>Paul Emery (UK)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>08.20</td>
<td>Ellen Gravallese (US)</td>
<td>Effects of the IL-17 pathway on inflammation, enthesitis, and bone in PsA</td>
</tr>
<tr>
<td>08.35</td>
<td>Xenofon Baraliakos (DE)</td>
<td>Back pain in PsA and axSpA: A critical comparison</td>
</tr>
<tr>
<td>08.55</td>
<td>Mikkel Østergaard (DK)</td>
<td>Real world evidence: The importance of comprehensive disease control</td>
</tr>
<tr>
<td>09.10</td>
<td>Peter Nash (AU)</td>
<td>IL-17A inhibition and data visualization: Comprehensive treatment for PsA</td>
</tr>
<tr>
<td>09.30</td>
<td>All</td>
<td>Panel discussion and conclusions</td>
</tr>
</tbody>
</table>

---

José A. Gómez-Puerta (ES)  
Alejandro Olivé-Marqués (ES)

GSK  
**Treatment timing considerations in biologic management of SLE: The long and short of it**

**Chair(s):**  
Alejandro Olivé-Marqués (ES)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Affiliation</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.30</td>
<td>Alejandro Olivé-Marqués (ES)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17.35</td>
<td>Alejandro Olivé-Marqués (ES)</td>
<td>Long- and short-term treatment goals in SLE</td>
</tr>
<tr>
<td>17.45</td>
<td>José A. Gómez-Puerta (ES)</td>
<td>Balancing the benefits and risks of treatment in SLE</td>
</tr>
<tr>
<td>18.05</td>
<td>Luca Iaccarino (IT)</td>
<td>When to start biologic therapy in SLE?</td>
</tr>
<tr>
<td>18.25</td>
<td>Andreas Schwarting (DE)</td>
<td>Experience with initiating biologic therapy earlier in the disease course</td>
</tr>
<tr>
<td>18.40</td>
<td>All</td>
<td>Faculty discussions</td>
</tr>
<tr>
<td>18.55</td>
<td>Alejandro Olivé-Marqués (ES)</td>
<td>Summing up and concluding remarks</td>
</tr>
</tbody>
</table>
### Boehringer Ingelheim
**Treatment of interstitial lung disease in systemic sclerosis and other autoimmune rheumatic diseases – A step forward**

**Chair(s):**
Oliver Distler (CH)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>Oliver Distler (CH)</td>
<td>Introduction</td>
</tr>
<tr>
<td>08.20</td>
<td>Anna-Maria Hoffmann-Vold (NO)</td>
<td>How should we screen for and monitor SSc-ILD?</td>
</tr>
<tr>
<td>08.40</td>
<td>Clive Kelly (UK)</td>
<td>Can we apply learnings from SSc-ILD to the screening and monitoring of ILDs in other autoimmune rheumatic diseases?</td>
</tr>
<tr>
<td>09.00</td>
<td>Oliver Distler (CH)</td>
<td>Are we a step closer to a new approach to the treatment of SSc-ILD and other ILDs associated with autoimmune rheumatic diseases?</td>
</tr>
<tr>
<td>09.20</td>
<td>All</td>
<td>Questions and answers</td>
</tr>
</tbody>
</table>

### AbbVie
**Transition to adulthood in clinical practice: How can we improve the experience of patients with JIA?**

**Chair(s):**
Alberto Martini (IT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>Alberto Martini (IT)</td>
<td>Welcome, introduction and objectives</td>
</tr>
<tr>
<td>08.20</td>
<td>Alberto Martini (IT)</td>
<td>Understanding the journey of a patient with JIA: The changing needs throughout adolescence into adulthood</td>
</tr>
<tr>
<td>08.40</td>
<td>Helen Foster (UK)</td>
<td>Assessing and transforming transition strategies: What do the guidelines advise?</td>
</tr>
<tr>
<td>09.00</td>
<td>Cristina Estrach (UK)</td>
<td>Setting up a successful transition service: What do I need to know?</td>
</tr>
<tr>
<td>09.15</td>
<td>Cristina Estrach (UK)</td>
<td>Practical implementation: Case reports on the successful transition of patients with JIA</td>
</tr>
<tr>
<td>09.35</td>
<td>All</td>
<td>Panel discussion and Q&amp;A</td>
</tr>
</tbody>
</table>

### Lilly
**The standard of care in rheumatoid arthritis: The BAR Is RAised**

**Chair(s):**
José María Álvaro-Gracia (ES)
Ronald van Vollenhoven (NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>José Maria Álvaro-Gracia (ES)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>08.15</td>
<td>Ronald van Vollenhoven (NL)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>08.20</td>
<td>Ernest Choy (UK)</td>
<td>Is there any new evidence on JAK inhibition and its clinical implications?</td>
</tr>
<tr>
<td>08.40</td>
<td>Peter Taylor (UK)</td>
<td>Treating to target and beyond</td>
</tr>
<tr>
<td>09.00</td>
<td>Eugen Feist (DE)</td>
<td>The test drive is over: What have we learnt using Baricitinib in clinical practice?</td>
</tr>
<tr>
<td>09.20</td>
<td>José María Álvaro-Gracia (ES)</td>
<td>Panel discussion and Q&amp;A</td>
</tr>
</tbody>
</table>

### Celgene
**Moderate PsA and perspectives from PDE4 inhibition**

**Chair(s):**
Rubén Queiro (ES)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>Rubén Queiro (ES)</td>
<td>Opening statements</td>
</tr>
<tr>
<td>08.20</td>
<td>Stefan Siebert (UK)</td>
<td>Challenges in PsA clinical practice: Tailoring treatment to patients’ profile</td>
</tr>
<tr>
<td>08.40</td>
<td>Dafna Gladman (CA)</td>
<td>Oligoarticular PsA: Lessons from longitudinal cohorts</td>
</tr>
<tr>
<td>09.05</td>
<td>Frank Behrens (DE)</td>
<td>Learnings from PDE4 inhibition: Optimising outcomes for moderate PsA</td>
</tr>
<tr>
<td>09.30</td>
<td>Rubén Queiro (ES)</td>
<td>Summary of the major learnings</td>
</tr>
<tr>
<td>09.35</td>
<td>All</td>
<td>Audience Q&amp;A</td>
</tr>
</tbody>
</table>
### 08.15 - 09.45  N117/N118

**Menarini Group**  
Painful conditions in rheumatological diseases - A therapeutic strategy

**Chair(s):**  
Serge Perrot (FR)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>Serge Perrot (FR)</td>
</tr>
<tr>
<td>08.30</td>
<td>Stefano Coaccioli (IT)</td>
</tr>
<tr>
<td>08.50</td>
<td>Serge Perrot (FR)</td>
</tr>
<tr>
<td>09.10</td>
<td>Magdi Hanna (UK)</td>
</tr>
<tr>
<td>09.30</td>
<td>All</td>
</tr>
</tbody>
</table>

### 17.30 - 19.00  N101/N102

**Rheumatology Today**  
a service by: Chugai  
supported by: Roche & Novartis

German rheumatologists present their personal EULAR congress highlights

**Chair(s):**  
Matthias Schneider (DE)

**Speakers:**  
Peer M. Aries (DE)  
Xenofon Baraliakos (DE)  
Frank Behrens (DE)  
Christof Iking-Konert (DE)  
Christof Specker (DE)  
Torsten Witte (DE)

**Round table experts:**  
Frank Buttgereit (DE)  
Jens Gert Kuipers (DE)  
Ulf Müller-Ladner (DE)

Presentation of six trials presented at EULAR 2019 featuring the following topics:
- Axial spondylarthritics
- Biologica monotherapy
- Connective tissue diseases
- Novelities in RA treatment
- Psoriatic arthritis
- Vasculitis

### 08.15 - 09.45  N111/N112

**GSK**  
From today’s reality, to tomorrow’s “Vision for Lupus”

**Chair(s):**  
Chiara Tani (IT)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.15</td>
<td>Chiara Tani (IT)</td>
</tr>
<tr>
<td>08.30</td>
<td>Patricia Cagnoli (US)</td>
</tr>
<tr>
<td>08.45</td>
<td>Chiara Tani (IT)</td>
</tr>
<tr>
<td>09.05</td>
<td>Chris Edwards (UK)</td>
</tr>
<tr>
<td>09.25</td>
<td>Sue Mayor &amp; Faculty</td>
</tr>
<tr>
<td>09.40</td>
<td>Chiara Tani (IT)</td>
</tr>
</tbody>
</table>

### 17.30 - 19.00  N117/N118

**RMEI**  
supported by Sanofi Genzyme & Regeneron Pharmaceuticals

Addressing real-world practice gaps in the management of RA

**Chair(s):**  
Paul Emery (UK)

**Faculty:**  
Leonard H. Calabrese (US)  
Ernest Choy (UK)

Dinner reception & posters review  
17.30

**Paul Emery (UK)**  
18.00  
Welcome and introductions

**Paul Emery (UK)**  
18.10  
What do current gaps mean for patients?

**All**  
18.20  
Panel discussion #1: Pathologic mechanisms in RA and implications for management
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.40</td>
<td>Panel discussion #2: Standards for disease monitoring to guide treatment</td>
</tr>
<tr>
<td>19.00</td>
<td>Panel discussion #3: Switching versus cycling and the role of new treatment options</td>
</tr>
<tr>
<td>19.20</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>

**Corbus Pharmaceuticals**

**The role of the endocannabinoid system in chronic inflammation and fibrosis**

**Chair(s):**
- Christopher Denton (UK)
- Tracy M. Frech (US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.30</td>
<td>Christopher Denton (UK)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17.55</td>
<td>Christopher Denton (UK)</td>
<td>Biology of the endocannabinoid system with a focus on inflammation and fibrosis</td>
</tr>
<tr>
<td>18.20</td>
<td>Tracy M. Frech (US)</td>
<td>Targeting endocannabinoid system as a potential therapeutic in inflammatory/fibrotic diseases</td>
</tr>
</tbody>
</table>